Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.
Автор: Life Science Connect
Загружено: 2025-11-23
Просмотров: 116
On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for emerging markets, and the shift from animal models to in silico modeling in preclinical research.
Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - https://podcasts.apple.com/us/podcast...
Spotify - https://open.spotify.com/show/5NhjpDe...
YouTube - • The Business Of Biotech Podcast
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
